Answers are grounded in this paper and cite their sources.
Retrospective cohort study reveals liver metastasis burden predicts overall survival in advanced pancreatic cancer, suggesting its utility for clinical risk stratification.
Background/Aim: The prognostic significance of the number of liver metastases in patients with advanced pancreatic cancer (APC) treated with nab-paclitaxel plus gemcitabine (AG) remains unclear. This study was performed to investigate the impact of the number of liver metastases on survival outcomes in this population. Patients and Methods: From January 2015 to July 2024, 103 patients with APC received AG as first-line chemotherapy at Higashiosaka City Medical Center. The patients were categorized into three groups based on contrast-enhanced computed tomography findings: no liver metastases (NLM), several liver metastases (SLM) (1-9), and multiple liver metastases (MLM) (≥10). Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Patient characteristics and clinical courses were compared between the non-MLM and MLM groups. Prognostic factors were analyzed using Cox regression models. Multivariate analysis identified the number of liver metastases as an independent prognostic factor for OS. Conclusion: The number of liver metastases in patients with APC treated with nab-paclitaxel plus gemcitabine may help stratify prognosis in clinical practice and could serve as a useful parameter for treatment decision making and for stratification in future clinical trials.
No takes yet. Share an insight, caveat, or question.
Iede et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: